TEVA, US8816242098

Teva stock: Higher guidance meets expanded biosimilars push

Published on 11/11/2026 at 16:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teva stock is in focus after higher 2026 revenue targets and a broader U.S. biosimilars alliance. Generic-drug pressure remains a key risk.

Teva advances its growth pivot

Teva raised its 2026 revenue outlook after innovative brands grew strongly in the third quarter.
The Samsung Bioepis deal expands Teva's U.S. immunology biosimilars portfolio.
Lower generic-drug sales remain a central execution risk for the transformation plan.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries raised its 2026 revenue outlook after reporting third-quarter results on November 3, while an expanded agreement with Samsung Bioepis added two FDA-approved immunology biosimilars to its U.S. portfolio. The company detailed the developments in its November 3 investor release.

Higher targets, mixed quarterly picture

Teva now expects 2026 revenue of USD 16.7 billion to USD 17.0 billion, compared with its previous range of USD 16.5 billion to USD 16.85 billion. The company also lifted its outlook for AUSTEDO, AJOVY and UZEDY, with the three innovative brands generating approximately USD 1.1 billion in third-quarter revenue and growing 33% year over year in local currency.

The quarter was not uniformly strong. Revenue declined 2% to USD 4.395 billion, mainly because of lower U.S. sales of generic lenalidomide amid increased competition. GAAP diluted earnings per share fell to USD 0.20 from USD 0.37 a year earlier, while non-GAAP diluted earnings per share rose to USD 0.86 from USD 0.78. The adjusted figures exclude items including legal settlements, impairment charges, restructuring expenses and acquired intellectual property research and development costs.

U.S. biosimilars portfolio expands

The Samsung Bioepis agreement covers infliximab-abda, a biosimilar to Remicade, and etanercept-ykro, a biosimilar to Enbrel. Teva will receive U.S. commercialization rights to etanercept-ykro at closing, while rights to infliximab-abda are scheduled to transfer in the third quarter of 2027. The transaction is expected to close by the end of 2026, subject to customary conditions.

Samsung Bioepis will retain manufacturing and regulatory responsibility, while the companies will share profits. Teva expects biosimilars revenue to exceed USD 0.8 billion in 2026, reaching its original 2027 target one year early. The agreement therefore supports the portfolio shift, but future returns depend on launch timing, competition and commercial execution.